Print this page
-
A Phase I Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors.
Protocol: 052103Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Any Site -
A Open-Label, Multicenter, Phase1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.
Protocol: 052102Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012107Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate